Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “BRAF Mutated Melanoma”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Testing effectiveness (Phase 2)Study completedNCT01928940
What this trial is testing

Japan PhI/II of GSK2118436 and GSK1120212 Combination in Subjects With BRAF V600E/K Mutation Positive Advanced Solid Tumors (Phase I Part) or Cutaneous Melanoma (Phase II Part)

Who this might be right for
Solid Tumours
GlaxoSmithKline 12
Not applicableStudy completedNCT03416933
What this trial is testing

Therapeutic Drug Monitoring of BRAF-mutated Advanced Melanoma

Who this might be right for
Melanoma (Skin)
Institut de Cancérologie de Lorraine 35
Not applicableStudy completedNCT03663647
What this trial is testing

Advanced Melanoma in Russian Experience

Who this might be right for
Cutaneous Melanoma, Stage IVBRAF V600 Mutation
MelanomaPRO, Russia 382
Testing effectiveness (Phase 2)Study completedNCT01894672
What this trial is testing

BRAF Inhibitor, LGX818, Utilizing a Pulsatile Schedule in Patients With Stage IV or Unresectable Stage III Melanoma Characterized by a BRAFV600 Mutation

Who this might be right for
Melanoma
Memorial Sloan Kettering Cancer Center 7
Testing effectiveness (Phase 2)Active Not RecruitingNCT03235245
What this trial is testing

Immunotherapy With Ipilimumab and Nivolumab Preceded or Not by a Targeted Therapy With Encorafenib and Binimetinib

Who this might be right for
Unresectable Stage III MelanomaStage IV Melanoma
European Organisation for Research and Treatment of Cancer - EORTC 271
Early research (Phase 1)Study completedNCT02082665
What this trial is testing

Effects of Dabrafenib on the Single Dose Pharmacokinetics (PK) of Rosuvastatin and Midazolam

Who this might be right for
Cancer
GlaxoSmithKline 6
Testing effectiveness (Phase 2)Ended earlyNCT01754376
What this trial is testing

Combined BRAF-Targeted Therapy & Immunotherapy for Melanoma

Who this might be right for
Melanoma
Massachusetts General Hospital 6
Testing effectiveness (Phase 2)Ended earlyNCT05926960
What this trial is testing

A Study Comparing 3 Study Medicines (Encorafenib, Binimetinib, Pembrolizumab) to 2 Study Medicines (Ipilimumab and Nivolumab) in Patients With Advanced Melanoma

Who this might be right for
Melanoma
Pfizer 38
Testing effectiveness (Phase 2)UnknownNCT05263453
What this trial is testing

HL-085+Vemurafenib to Treat Advanced Melanoma Patients With BRAF V600E/K Mutation

Who this might be right for
Melanoma
Shanghai Kechow Pharma, Inc. 104
Testing effectiveness (Phase 2)Study completedNCT00866177
What this trial is testing

MEK Inhibitor AZD6244 in Treating Patients With Stage III or Stage IV Melanoma

Who this might be right for
Recurrent MelanomaStage III Skin MelanomaStage IV Skin Melanoma
National Cancer Institute (NCI) 167
Early research (Phase 1)Ended earlyNCT01940809
What this trial is testing

Ipilimumab With or Without Dabrafenib, Trametinib, and/or Nivolumab in Treating Patients With Melanoma That Is Metastatic or Cannot Be Removed by Surgery

Who this might be right for
BRAF V600E Mutation PresentBRAF V600K Mutation PresentMetastatic Melanoma+5 more
National Cancer Institute (NCI) 15
Testing effectiveness (Phase 2)Ended earlyNCT01562899
What this trial is testing

MEK162 and AMG 479 in Patients With Selected Solid Tumors

Who this might be right for
Metastatic Pancreatic AdenocarcinomaBRAF Mutated Melanoma
Pfizer 77
Testing effectiveness (Phase 2)Study completedNCT01037127
What this trial is testing

Study to Determine the Effectiveness of GSK1120212 in BRAF Mutation-positive Melanoma Previously Treated With or Without a BRAF Inhibitor

Who this might be right for
Cancer
GlaxoSmithKline 97
Not applicableStudy completedNCT04911998
What this trial is testing

A Prospective Observational Study on Targeted Therapy for Unresectable or Metastatic BRAFV600E Mutant Melanoma Patients

Who this might be right for
Melanoma (Skin)Metastatic MelanomaBRAF V600 Mutation
Pierre Fabre Medicament 400
Testing effectiveness (Phase 2)Looking for participantsNCT06887088
What this trial is testing

Encorafenib and biNimetinib Followed by CEmiplimab and FiAnLimab in Patients With BRAF Mutant melanOma and Symptomatic Brain Metastases

Who this might be right for
Melanoma BRAF V600E/K MutatedMelanoma and Brain Metastases
Grupo Español Multidisciplinar de Melanoma 33
Testing effectiveness (Phase 2)Study completedNCT02836548
What this trial is testing

HDAC Inhibitor Vorinostat in Resistant BRAF V600 Mutated Advanced Melanoma

Who this might be right for
MelanomaSkin Neoplasms
The Netherlands Cancer Institute 33
Early research (Phase 1)WithdrawnNCT02068079
What this trial is testing

A Pilot Study of Trientine With Vemurafenib for the Treatment BRAF Mutated Metastatic Melanoma

Who this might be right for
Melanoma
Duke University
Early research (Phase 1)Temporarily pausedNCT04418167
What this trial is testing

JSI-1187-01 Monotherapy and in Combination With Dabrafenib for Advanced Solid Tumors With MAPK Pathway Mutations

Who this might be right for
Solid Tumors
JS InnoPharm, LLC 71
Testing effectiveness (Phase 2)Study completedNCT02768207
What this trial is testing

Detect V-Raf Murine Sarcoma Viral Oncogene Homolog B1 (BRAF) V600 Mutation on Cell-Free Deoxyribonucleic Acid (cfDNA) From Plasma in Participants With Advanced Melanoma

Who this might be right for
Metastatic Melanoma
Hoffmann-La Roche 40
Post-approval studies (Phase 4)WithdrawnNCT07092410
What this trial is testing

Surgical or Radiotherapeutic Intervention Concerning Large Singular Stable to Progressive Metastases in Patients With BRAFV600-mutated Melanoma Receiving Treatment With Encorafenib + Binimetinib

Who this might be right for
Melanoma BRAF V600E/K Mutated
SRH Wald-Klinikum Gera GmbH
Next Page